Roden Dan M, Altman Russ B, Benowitz Neal L, Flockhart David A, Giacomini Kathleen M, Johnson Julie A, Krauss Ronald M, McLeod Howard L, Ratain Mark J, Relling Mary V, Ring Huijun Z, Shuldiner Alan R, Weinshilboum Richard M, Weiss Scott T
Vanderbilt University, Nashville, Tennessee, USA.
Ann Intern Med. 2006 Nov 21;145(10):749-57. doi: 10.7326/0003-4819-145-10-200611210-00007.
The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The sequencing of the human genome and the cataloguing of variants across human genomes are the enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea that genomic variability underlies variability in drug responses. However, there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways; relating disease genes to drug response genes; precisely defining drug response phenotypes; and addressing analytic, ethical, and technological issues involved in generation and management of large drug response data sets. Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients.
药物治疗的结果往往不可预测,从有益效果到无效再到严重不良反应。单基因变异是导致这种不可预测性的一个公认原因,由此定义了药物遗传学领域(见术语表)。此类变异可能涉及控制药物代谢、药物转运、疾病易感性或药物靶点的基因。人类基因组测序以及人类基因组变异编目是新兴的药物基因组学领域(见术语表)的基础资源,该领域检验了基因组变异性是药物反应变异性基础的这一观点。然而,要将快速积累的基因组信息应用于理解药物反应的变异性,还必须克服许多挑战,包括确定候选基因和途径;将疾病基因与药物反应基因联系起来;精确界定药物反应表型;以及解决生成和管理大型药物反应数据集所涉及的分析、伦理和技术问题。克服这些挑战有望改进新药研发,并最终实现为个体患者选择合适药物和剂量的个体化。